Theriva Biologics, Inc.
NYSE · Healthcare · Pharmaceutical Preparations · Rockville, MD
TOVX chart
What traders are saying about $TOVX
Latest postsTheriva Biologics, Inc. news
- Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine
Yahoo Finance ·
- Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
Yahoo Finance ·
- Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Yahoo Finance ·
- Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Yahoo Finance ·
- Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
Yahoo Finance ·
- Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
Yahoo Finance ·
- Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
Yahoo Finance ·
- Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
Yahoo Finance ·
- Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
Yahoo Finance ·
- Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
Yahoo Finance ·
- Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
Yahoo Finance ·
- Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design
Yahoo Finance ·
Theriva Biologics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$23.7M | -$25.7M | -$18.3M | -$19.7M |
| Diluted EPS | $-2.08 | $-19.03 | $-28.48 | $-1.31 |
| Total assets (year end) | $38.2M | $35.4M | $55.2M | $71.9M |
| Cash and equivalents (year end) | $13.1M | $11.6M | $23.2M | $41.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Theriva Biologics, Inc.
- Ticker
- TOVX (NYSE)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Rockville, MD
- Incorporated in
- NV
- Fiscal year end
- December 31
- SEC CIK
- 894158
- Former names
- Synthetic Biologics, Inc., ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC.
Frequently asked questions
What exchange is Theriva Biologics, Inc. listed on?
Theriva Biologics, Inc. trades on the NYSE under the ticker symbol TOVX.
What industry is Theriva Biologics, Inc. in?
Theriva Biologics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Theriva Biologics, Inc. headquartered?
Theriva Biologics, Inc.'s business address on file with the SEC is in Rockville, MD.
When does Theriva Biologics, Inc.'s fiscal year end?
Theriva Biologics, Inc.'s fiscal year ends on December 31.
How much revenue did Theriva Biologics, Inc. report?
Theriva Biologics, Inc. reported $0 in revenue for calendar year 2011, according to its SEC filings.